Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Leukemia, acute lymphocytic (ALL), child
Stage/Subtype:  childhood acute lymphoblastic leukemia in remission
Trial Type:  Treatment
Results 1-25 of 43 for your search:
Start Over
Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)
Status: Active
Phase: Phase III
Type: Treatment
Age: 1 to 65
Trial IDs: BMTCTN1301, NCI-2015-01813, U01HL069294, NCT02345850
Efficacy and Safety of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment
Status: Not yet active
Phase: Phase III
Type: Supportive care, Treatment
Age: 12 and over
Trial IDs: SHP620-303, NCI-2016-01720, 2015-004725-13, NCT02931539
Alemtuzumab Before Donor Stem Cell Transplant in Treating Patients With Hematologic Diseases
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 70 and under
Trial IDs: HIMSUM, NCI-2012-00639, NCT00058825
Multi-Virus-Specific Donor T Cells in Treating Patients With B Cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, or Non-Hodgkin Lymphoma Who Have Undergone Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 80 and under
Trial IDs: MULTIPRAT, NCI-2012-00636, H-23637, NCT00840853
Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 6 montha to 70
Trial IDs: J1055, NCI-2011-00377, NCT01203722
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 55 and under
Trial IDs: MT2005-10, NCI-2010-01444, 2005LS043, UMN-2005LS043, UMN-BMT-MT2005-10, UMN-MT2005-10, UMN-0507M71475, NCT00309842
Low-Dose Chemotherapy, Low-Dose Total-Body Irradiation, and Anti-Thymocyte Globulin Followed by Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancy or Kidney Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2001-10, NCI-2010-02155, 0108M06725, 2001LS058, UMN-2001LS058, UMN-MT2001-10, NCT00303719
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation and Anti Thymocyte Globulin before Umbilical Cord Blood Transplantation in Treating Patients with Hematological Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 70
Trial IDs: MT2005-02, NCI-2010-01415, 2005LS036, UMN-2005LS036, UMN-MT-2005-02, UMN-0507M70121, NCT00305682
Busulfan, Melphalan, and Fludarabine Phosphate Followed by Donor Umbilical Cord Blood Transplant in Treating Younger Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome
Status: Active
Phase: Phase II
Type: Treatment
Age: 2 and under at diagnosis
Trial IDs: MT2005-25, NCI-2010-02159, 2005LS075, HS# 0511M77206, UMN-2005LS075, UMN-MT2005-25, UMN-0511M77206, NCT00357565
Mismatched Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and under
Trial IDs: IUCRO-0184, NCI-2011-02351, NCT00593554
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematologic Disease
Status: Active
Phase: Phase II
Type: Treatment
Age: 6 months to 45 years
Trial IDs: 2010.00, NCI-2010-00190, 2010, FHCRC 2010.00, Protocol 2010, 6095, NCT00719888
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2239.00, NCI-2009-01551, 2239, FHCRC-2239.00, 6722, FHCRC-IR-6722, NCT00723099
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients with Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
Status: Active
Phase: Phase II
Type: Treatment
Age: Under 65
Trial IDs: 2275.00, NCI-2010-00299, 2275, FHCRC-2275.00, IR-6800, NCT00796068
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, 2212, NCT00968630
Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2372.00, NCI-2009-01433, 2372, NCT01028716
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Donor Umbilical Cord Blood Transplant After Combination Chemotherapy and Total-Body Irradiation in Treating Younger Patients With High-Risk Hematologic Malignancies
Status: Temporarily closed
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: UCBT01, NCI-2011-03700, NCT01328496
Leuprolide Acetate in Improving Immune Recovery and 18F FLT PET/CT in Predicting Immune Recovery after Donor Bone Marrow Transplant in Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 9 to 55
Trial IDs: 11-C-0136, NCI-2013-01485, 110136, P10780, NCT01338987
Combination Chemotherapy and Ofatumumab in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2010-0708, NCI-2011-01061, NCT01363128
Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611
Safety Study of Cord Blood Units for Stem Cell Transplants
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 130116, NCI-2014-01832, 13-H-0116, NCT01861093
Chemotherapy before and after Donor Bone Marrow Transplant in Treating Younger Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 6 months to 25 years
Trial IDs: J13161, NCI-2014-01899, CIR00009809, NA_00091665, NCT02120157
Start Over